文献速递乳腺MRUS

对MRI检出的额外乳腺病灶进行第二眼超声联合容积导航的六年前瞻性评估

Six-year prospective evaluation of second-look US with volume navigation for MRI-detected additional breast lesions.
PubMed 文献 · Eur Radiol · 2018-10-15

该前瞻性研究在两家机构纳入1437例患者的1930次俯卧位乳腺MRI检查,对MRI检出的额外病灶行第二眼超声,隐匿者行仰卧位增强MRI与超声容积导航共定位。第二眼超声联合容积导航可检出大量第二眼超声隐匿的额外乳腺病灶,并安全活检其中较多恶性病灶,减少MRI引导活检需求。

要点

  • 第二眼超声联合容积导航可检出大量常规第二眼超声隐匿的额外乳腺病灶。
  • 容积导航下可对病灶安全活检,不受病灶位置和距皮肤深度影响。
  • 该技术可减少对MRI引导活检的需求。

核心结论

  • 第二眼超声联合容积导航可有效检出大量第二眼超声隐匿的额外乳腺病灶,并安全活检其中较多恶性病灶,不受病灶距皮肤深度或位置影响。

研究设计与样本

  • 前瞻性研究,两家机构经IRB批准,纳入1437例患者的1930次连续俯卧位乳腺MRI检查;对MRI检出的额外病灶行第二眼超声,隐匿者行仰卧位增强MRI与超声容积导航共定位,乳腺肥大者直接行MRI引导活检,以病理检查为参考标准,采用单因素方差分析和卡方检验。

诊断标准与关键数值

  • 490次MRI检查(25.4%,490/1930)检出至少一个额外病灶,共722个仅MRI检出病灶;第二眼超声检出549个额外病灶(23±8 mm),其中病理良性362个(65.9%,362/549)、恶性187个(34.1%,187/549);第二眼超声联合容积导航检出151个额外病灶(17±9 mm,p=n.s.),其中良性67个(44.4%,67/151)、恶性84个(55.6%,84/151);MRI引导活检22个额外病灶(22±8 mm,p=n.s.),病理良性20个(90.9%,20/22)、恶性2个(9.1%,2/22)。

临床应用与阅片要点

  • 第二眼超声组肿块性病变显著多于其他组(p<0.001);三组间病灶大小无显著差异(p=0.729);原文结论认为第二眼超声联合容积导航可有效检出隐匿额外病灶并安全活检恶性病灶、减少MRI引导活检需求。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this study is to present a 6-year prospective evaluation of second-look ultrasound (US) using volume navigation (V Nav) for MRI-detected additional breast lesions.

METHODS: After IRB approvals in both institutions, 1930 consecutive prone MRI breast examinations in 1437 patients were prospectively evaluated. All patients with an MRI-detected additional lesion underwent second-look US, and if occult, contrast-enhanced MRI in supine position was performed for US and MRI co-registration. For patients with breast hypertrophy, MRI-guided biopsy was performed directly. Pathologic examination was the standard of reference. One-way ANOVA and chi-square tests were used.

RESULTS: In 490 MRI examinations (25.4%, 490/1930), at least one additional breast lesion was detected for a total of 722 only MRI-detected lesions. Second-look US identified 549 additional lesions (23 ± 8 mm); 362 (65.9%, 362/549) proved benign at pathology and 187 (34.1%, 187/549) malignant. Second-look US with V Nav identified 151 additional lesions (17 ± 9 mm, p = n.s.); 67 (44.4%, 67/151) proved benign at pathology and 84 (55.6%, 84/151) malignant. MRI-guided biopsy was performed on 22 additional breast lesions (22 ± 8 mm, p = n.s.); pathology revealed 20 (90.9%, 20/22) benign lesions and 2 (9.1%, 2/22) malignant ones. Mass lesions were significantly higher in the second-look US group (p < 0.001). No significant difference in lesion dimension was found between the three groups (p = 0.729).

CONCLUSIONS: Second-look US with V Nav can be effective in detecting a large number of additional breast lesions occult at second-look US and to biopsy a significant number of malignant lesions safely and irrespective of distance from skin or lesion position.

KEY POINTS: • Second-look US with volume navigation is effective in detecting occult additional lesions. • Permits safe biopsies irrespective of position and depth • Reduces the need for MRI-guided biopsy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fausto A, Bernini M, La Forgia D, et al. Six-year prospective evaluation of second-look US with volume navigation for MRI-detected additional breast lesions. Eur Radiol. 2018. PMID: 30324386. doi:10.1007/s00330-018-5765-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。